Dr. Flaherty on Resistance in BRAF-Mutant Melanoma

Keith T. Flaherty, MD
Published: Tuesday, Oct 11, 2016



Keith T. Flaherty, MD, director of Developmental Therapeutics at the Cancer Center of Massachusetts General Hospital, discusses resistance that develops in patients with BRAF-mutant melanoma.

Resistance to targeted therapies is inevitable, Flaherty explains, and is likely experienced in patients within 2 years. In a 2-year follow-up of the COMBI-d study, however, a large proportion of patients did not have disease progression and were doing well on therapy with the combination of dabrafenib (Tafinlar)/trametinib (Mekinist), he adds. Additionally, the 3-year data showed that there is a subgroup of patients with BRAF mutations with a less likely chance of resisting therapy.

These findings should lead to a new perception about drug resistance in the melanoma community, he explains.


Keith T. Flaherty, MD, director of Developmental Therapeutics at the Cancer Center of Massachusetts General Hospital, discusses resistance that develops in patients with BRAF-mutant melanoma.

Resistance to targeted therapies is inevitable, Flaherty explains, and is likely experienced in patients within 2 years. In a 2-year follow-up of the COMBI-d study, however, a large proportion of patients did not have disease progression and were doing well on therapy with the combination of dabrafenib (Tafinlar)/trametinib (Mekinist), he adds. Additionally, the 3-year data showed that there is a subgroup of patients with BRAF mutations with a less likely chance of resisting therapy.

These findings should lead to a new perception about drug resistance in the melanoma community, he explains.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Evolving Roles for Targeted Melanoma Therapies: Assessing Rapid Progress in the Field and Looking Toward Future CombinationsFeb 28, 20191.5
Publication Bottom Border
Border Publication
x